Form 4: BioLife Solutions Director Sells BLFS Stock

BioLife Solutions Director Amy DuRoss reported selling 6,000 shares of common stock over three days in November 2025.

Summary

• Amy DuRoss, a Director of BioLife Solutions Inc. (BLFS), reported sales of common stock.
• The transactions occurred on November 19, 2025, November 20, 2025, and November 21, 2025.
• A total of 6,000 shares of common stock were sold across these dates.
• The sales were executed at prices ranging from $24.50 to $26.00 per share.
• Following these transactions, DuRoss beneficially owns 24,687 shares of common stock directly.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating pre-scheduled sales.

Sentiment

Score: 5

Explanation: The filing reports routine insider selling by a director under a Rule 10b5-1 plan, which is a pre-arranged trading plan. While selling reduces insider ownership, the pre-scheduled nature mitigates immediate negative implications, leading to a neutral sentiment.

Positives

• The transactions were made pursuant to a Rule 10b5-1 plan, indicating pre-scheduled sales rather than an immediate reaction to new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Risks

• Market perception of insider selling could lead to short-term negative sentiment for BLFS stock.

Future Outlook

NA

Industry Context

Insider transactions are a routine part of public company disclosures. While a single Form 4 filing doesn't typically indicate a major shift in industry trends, significant insider selling across multiple executives or over an extended period can sometimes signal concerns about future company performance relative to the broader industry. In this case, it is a single director's pre-scheduled sales.

Stakeholder Impact

• Shareholders: May observe a slight negative sentiment due to insider selling, though the 10b5-1 plan context is important for understanding the nature of the transactions.

Key Dates

Keywords

BIOLIFE SOLUTIONS, BLFS, Form 4, insider trading, stock sale, director, Amy DuRoss, 10b5-1 plan